A

1

Characteristics of the pathogen?

Laboratory study

Van der Worp [37]^{3}

A

2

Subtypes, serotypes and local epidemiology of the pathogen?

Laboratory study

Van der Worp [37]

  
Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

A

3

Modes of transmission?

Animal study

Van der Worp [37]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Case series

Cho [30]

  
Casecontrol study

Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44]

B

4

Incidence of the disease?

Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

B

5

Prevalence/seroprevalence of the disease?

Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

B

6

Consequences or sequelae of the disease (hospitalization/mortality/complications/disabilities)?

Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

Case series

Cho [30]

Case report

Cho [30]

B

7

Perception of the disease in the target population?

Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Focus groups

NICE [48], CASP [36]

  
Interview study
 
C

8

Sensitivity of tests?

Diagnostic test accuracy study

SIGN [42]

C

9

Specificity of tests?

Diagnostic test accuracy study

SIGN [42]

D

10

Risk factors (for transmission/colonization/infection/disease/exacerbation/complication)?

Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

Casecontrol study

Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44]

Ecological study

NICE [47]

Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

  
Animal study

Van der Worp [37]

E

11

Effects of intervention (in terms of efficacy/effectiveness/surrogate markers/adverse events/harms)?

Controlled beforeandafter study

Downs [31], NICE [46], EPHPP [38]

  
RCT

Cochrane [35], Downs [31], SIGN [39], NICE [46], EPHPP [38]

  
NRCT

Downs [31], NICE [46], EPHPP [38]

  
Clusterrandomized trial

Downs [31], NICE [46], EPHPP [38]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Casecontrol study

Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44]

  
Uncontrolled beforeandafter study

Downs [31], NICE [46], EPHPP [38]

  
Ecological study

NICE [47]

  
Interrupted time series

EPOC [50], EPHPP [38]

  
Selfcontrolled case series

Cho [30], NOS [44], SIGN [41]

F

12

Feasible to implement?

Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Focus groups

NICE [48], CASP [36]

  
Interview study
 
F

13

Costeffectiveness of the intervention?

Costeffectiveness (benefit, consequence) analysis

SIGN [43], NICE [49], QHES [34]

  
Costutility analysis

QHES [34]

F

14

Acceptable to stakeholders?

Focus groups

NICE [48], CASP [36]

  
Interview study
 
  
Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

F

15

Equitable?

Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

F

16

Enablers/barriers to success?

Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

  
Interview study (observation)

NICE [48], CASP [36]

  
Document analysis
 
  
Focus groups
 
  
Process evaluation
 
F

17

Coverage rates for positive population level effects?

Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Noneconomic modeling study

SIGN [43], NICE [49]

F

18

Communication of advice?

RCT

Cochrane [35], Downs [31], SIGN [39], NICE [46], EPHPP [38]

  
NRCT

Downs [31], NICE [46], EPHPP [38]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Crosssectional study

AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47]

  
Focus groups

NICE [48], CASP [36]

  
Interview study
 
F

19

Weighing and valuing of population preferences?

Crosssectional study

AlJader [33], Loney [32], Hoy [5], Cho [30], NICE [47]

  
Focus groups

NICE [48], CASP [36]

  
Interview study
 
F

20

Effectiveness of alternative measures?

Controlled beforeafter study

Downs [31], NICE [46], EPHPP [38]

  
RCT

Cochrane [35], Downs [31], SIGN [39], NICE [46], EPHPP [38]

  
NRCT

Downs [31], NICE [46], EPHPP [38]

  
Clusterrandomized trial

Downs [31], NICE [46], EPHPP [38]

  
Cohort study

Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44]

  
Casecontrol study

Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44]

  
Uncontrolled beforeafter study

Downs [31], NICE [46], EPHPP [38]

  
Ecological study

NICE [47]

  
Interrupted time series

EPOC [50], EPHPP [38]

  
Selfcontrolled case series

Cho [30], NOS [44], SIGN [41]
